Brasília – Brazilian pharmaceutical company EMS announced on Friday that local pharmacies will begin selling its injector pens for the treatment of diabetes and obesity starting August 4.

The pens are manufactured in Brazil and use liraglutide as the active ingredient — the same substance found in Saxenda, developed by Novo Nordisk, which has shown consistent benefits in controlling blood glucose levels and aiding weight loss.

Saxenda belongs to the same class of medications as Novo Nordisk’s blockbuster drug Ozempic, widely used off-label for weight loss.

Source: Reuters

Would you like a complete analysis of this topic?
Contact us at pharmabrnews@gmail.com